Novo Nordisk A/S, which faces higher demand for its diabetes and weight-loss drugs than it can meet, signed a long-term agreement with Ypsomed Holding AG for the supply of auto-injectors. Ypsomed is ...

Sept 20 (Reuters) - Swiss medical technology company Ypsomed YPSN.S announced on Wednesday a long-term supply deal with Novo Nordisk NOVOb.CO for autoinjectors, the latest sign of how the Danish ...

The Swiss diabetes hardware company Ypsomed is selling off its insulin pen needle and blood sugar monitoring operations, as it turns its attention toward its drug autoinjectors and digital insulin ...

(Reuters) -Swiss medical technology company Ypsomed announced on Wednesday a long-term supply deal with Novo Nordisk for autoinjectors, the latest sign of how the Danish drugmaker's weight-loss drug ...

Sept 20 (Reuters) - Swiss medical technology company Ypsomed (YPSN.S), opens new tab announced on Wednesday a long-term supply deal with Novo Nordisk (NOVOb.CO), opens new tab for autoinjectors, the ...

Novo Nordisk has spent the last two years scrambling to keep up with skyrocketing demand for its blockbuster GLP-1 drugs, the obesity-focused Wegovy and Type 2 diabetes med Ozempic, forcing it to ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced ...